Market Cap 2.10B
Revenue (ttm) 510.17M
Net Income (ttm) 146.93M
EPS (ttm) N/A
PE Ratio 13.31
Forward PE 12.17
Profit Margin 28.80%
Debt to Equity Ratio 0.47
Volume 2,266,700
Avg Vol 2,354,262
Day's Range N/A - N/A
Shares Out 223.99M
Stochastic %K 8%
Beta 0.78
Analysts Sell
Price Target $15.60

Company Profile

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the tre...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 478 5552
Fax: 201 478 5553
Address:
465 State Route 17, Ramsey, United States
et1000
et1000 Sep. 11 at 11:33 PM
Ticker MLEC is the next nano float runner ! Every small float ticker has been running almost 500% recently Would not be surprised if they send MLEC up next. MLEC starting to make its move now! Only 573k shares outstanding! 💎 $XE $MRVL $ADMA $ELPW filing
0 · Reply
BeefStewart
BeefStewart Sep. 11 at 5:59 PM
$ADMA I believe there is a significant disconnect between the current share price and the underlying value of the company. This disconnect is not necessarily due to this being a speculative investment, in my view. On the contrary, it looks to me like the price reflects a loss of faith in management's ability to correctly forecast growth. If there are buyers with deep pockets who still believe in the growth story of ASCENIV, I would consider the possibility of said buyers being interested in making an attempt to buy this business for a hefty, yet reasonable premium before the market learns if the growth story of ASCENIV is proven to be real in the coming quarters. Within the last 12 months, we've seen the share price at more than double the current levels, and the short report, in concert with a weakening environment for BIVIGAM, created a perfect storm-like scenario wherein the share price cratered. I believe the worst is behind ADMA. Good luck everyone!
0 · Reply
BabetteCH
BabetteCH Sep. 11 at 3:20 PM
$ADMA If you analyze the investors in detail on fintel.io, you’ll see that there have indeed been some interesting moves pointing toward activist tendencies.
1 · Reply
BeefStewart
BeefStewart Sep. 11 at 3:18 PM
$ADMA If someone offered $17 per share to acquire this tomorrow, I think there would be a real conversation about that... Ultimately, $18-$20 per share would be hard to outright refuse at this time, in my opinion.
0 · Reply
6RickyBobby9
6RickyBobby9 Sep. 10 at 9:43 PM
$ADMA Should be $100
0 · Reply
BeefStewart
BeefStewart Sep. 10 at 3:41 PM
0 · Reply
BeefStewart
BeefStewart Sep. 9 at 6:40 PM
$ADMA In my opinion, this is a takeover candidate.
1 · Reply
Princeredyr
Princeredyr Sep. 9 at 5:53 PM
$ADMA this channel is ridiculously boring .
1 · Reply
BeefStewart
BeefStewart Sep. 8 at 3:12 PM
$ADMA Bad economy or not, there's nothing quite like ASCENIV, and the fact that it's already doing as well as it is proves to me that its current success is no fluke. There's no substitute for the feeling of having an angry medical professional passionately squirting a hot load of payor-covered ASCENIV allover an immunocompromised face as it drips down the patient's chin and they relentlessly beg for more. Now, I'm no healthcare worker, but that's how I imagine the drug is administered if it's anything like my visits to my Urologist every week for what he says are mandatory physical examinations 😬😳🫣
2 · Reply
Princeredyr
Princeredyr Sep. 8 at 12:05 PM
$ADMA with all the misses in cardio and muscle it’s great to have a cash generating , de risked asset (Asceniv)
0 · Reply
Latest News on ADMA
Adma Biologics reports Q2 EPS 16c, consensus 16c

2026-08-05T21:01:21.000Z - 5 weeks ago

Adma Biologics reports Q2 EPS 16c, consensus 16c


ADMA Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 5 weeks ago

ADMA Biologics Earnings Call Transcript: Q2 2026


ADMA Biologics Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 5 weeks ago

ADMA Biologics Earnings release: Q2 2026


ADMA Biologics Quarterly report: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 5 weeks ago

ADMA Biologics Quarterly report: Q2 2026


Adma Biologics price target lowered to $17 from $20 at Mizuho

2026-07-15T11:25:44.000Z - 1 month ago

Adma Biologics price target lowered to $17 from $20 at Mizuho


20 growth stocks priced as value stocks

Jun 15, 2026, 10:53 AM EDT - 2 months ago

20 growth stocks priced as value stocks

AMG ANIP ARR BILL CG DAN EFC


Adma Biologics resumed with an Outperform at Raymond James

2026-06-10T11:40:39.000Z - 3 months ago

Adma Biologics resumed with an Outperform at Raymond James


ADMA Biologics Transcript: AGM 2026

Jun 2, 2026, 10:00 AM EDT - 3 months ago

ADMA Biologics Transcript: AGM 2026


Adma Biologics price target lowered to $20 from $24 at Mizuho

2026-05-07T16:02:55.000Z - 4 months ago

Adma Biologics price target lowered to $20 from $24 at Mizuho


Adma Biologics reports Q1 EPS 19c, consensus 20c

2026-05-07T00:37:49.000Z - 4 months ago

Adma Biologics reports Q1 EPS 19c, consensus 20c


Adma Biologics sees FY26 revenue $530M-$560M, consensus $629.1M

2026-05-07T00:36:02.000Z - 4 months ago

Adma Biologics sees FY26 revenue $530M-$560M, consensus $629.1M


ADMA Biologics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 months ago

ADMA Biologics Earnings Call Transcript: Q1 2026


ADMA Biologics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 months ago

ADMA Biologics Earnings release: Q1 2026


ADMA Biologics Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 months ago

ADMA Biologics Quarterly report: Q1 2026


Adma Biologics announces FDA approval for Asceniv sBLA

2026-05-04T11:31:54.000Z - 4 months ago

Adma Biologics announces FDA approval for Asceniv sBLA


Adma Biologics initiated with a Buy at Canaccord

2026-04-21T09:25:41.000Z - 4 months ago

Adma Biologics initiated with a Buy at Canaccord


Adma Biologics initiated with a Buy at Canaccord

2026-04-20T20:45:12.000Z - 4 months ago

Adma Biologics initiated with a Buy at Canaccord


ADMA Biologics Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 5 months ago

ADMA Biologics Proxy statement: Proxy filing


ADMA Biologics Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 5 months ago

ADMA Biologics Proxy statement: Proxy filing


Adma Biologics price target lowered to $24 from $30 at Mizuho

2026-04-13T14:43:12.000Z - 5 months ago

Adma Biologics price target lowered to $24 from $30 at Mizuho


Adma Biologics falls -15.9%

2026-03-26T16:06:09.000Z - 5 months ago

Adma Biologics falls -15.9%


Adma Biologics falls -19.9%

2026-03-26T14:07:02.000Z - 5 months ago

Adma Biologics falls -19.9%


et1000
et1000 Sep. 11 at 11:33 PM
Ticker MLEC is the next nano float runner ! Every small float ticker has been running almost 500% recently Would not be surprised if they send MLEC up next. MLEC starting to make its move now! Only 573k shares outstanding! 💎 $XE $MRVL $ADMA $ELPW filing
0 · Reply
BeefStewart
BeefStewart Sep. 11 at 5:59 PM
$ADMA I believe there is a significant disconnect between the current share price and the underlying value of the company. This disconnect is not necessarily due to this being a speculative investment, in my view. On the contrary, it looks to me like the price reflects a loss of faith in management's ability to correctly forecast growth. If there are buyers with deep pockets who still believe in the growth story of ASCENIV, I would consider the possibility of said buyers being interested in making an attempt to buy this business for a hefty, yet reasonable premium before the market learns if the growth story of ASCENIV is proven to be real in the coming quarters. Within the last 12 months, we've seen the share price at more than double the current levels, and the short report, in concert with a weakening environment for BIVIGAM, created a perfect storm-like scenario wherein the share price cratered. I believe the worst is behind ADMA. Good luck everyone!
0 · Reply
BabetteCH
BabetteCH Sep. 11 at 3:20 PM
$ADMA If you analyze the investors in detail on fintel.io, you’ll see that there have indeed been some interesting moves pointing toward activist tendencies.
1 · Reply
BeefStewart
BeefStewart Sep. 11 at 3:18 PM
$ADMA If someone offered $17 per share to acquire this tomorrow, I think there would be a real conversation about that... Ultimately, $18-$20 per share would be hard to outright refuse at this time, in my opinion.
0 · Reply
6RickyBobby9
6RickyBobby9 Sep. 10 at 9:43 PM
$ADMA Should be $100
0 · Reply
BeefStewart
BeefStewart Sep. 10 at 3:41 PM
0 · Reply
BeefStewart
BeefStewart Sep. 9 at 6:40 PM
$ADMA In my opinion, this is a takeover candidate.
1 · Reply
Princeredyr
Princeredyr Sep. 9 at 5:53 PM
$ADMA this channel is ridiculously boring .
1 · Reply
BeefStewart
BeefStewart Sep. 8 at 3:12 PM
$ADMA Bad economy or not, there's nothing quite like ASCENIV, and the fact that it's already doing as well as it is proves to me that its current success is no fluke. There's no substitute for the feeling of having an angry medical professional passionately squirting a hot load of payor-covered ASCENIV allover an immunocompromised face as it drips down the patient's chin and they relentlessly beg for more. Now, I'm no healthcare worker, but that's how I imagine the drug is administered if it's anything like my visits to my Urologist every week for what he says are mandatory physical examinations 😬😳🫣
2 · Reply
Princeredyr
Princeredyr Sep. 8 at 12:05 PM
$ADMA with all the misses in cardio and muscle it’s great to have a cash generating , de risked asset (Asceniv)
0 · Reply
Princeredyr
Princeredyr Sep. 4 at 6:07 PM
$ADMA I more then doubled my shares today . GLTA
1 · Reply
Merlintrader
Merlintrader Sep. 3 at 6:02 PM
ADMA Biologics (Nasdaq: $ADMA): Q2 2026 Results, ASCENIV Growth, BIVIGAM Stabilization, Margins and the Revenue-Quality Test Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/adma-biologics-stock-hub/
0 · Reply
mcclain23theoracle
mcclain23theoracle Sep. 3 at 2:55 PM
$ADMA it's cause I bought...my bad guys 🥹
0 · Reply
apc62657
apc62657 Sep. 2 at 11:17 PM
$ADMA looks like there a few healthcare conferences in September. Lets see if Adam attends one and starts to turn this ship around
0 · Reply
mcclain23theoracle
mcclain23theoracle Sep. 2 at 5:19 PM
$ADMA 🤔 Are you on Robinhood? If not, sign up with my link to claim a stock reward! https://join.robinhood.com/anthonm9223
1 · Reply
Wellseesometime
Wellseesometime Sep. 1 at 8:00 PM
$ADMA what is the floor on this stock? Fundamentally, it seems to be doing ok but keeps dropping. I'm not a long time owner - 2 years - but this is disheartening.
0 · Reply
BeefStewart
BeefStewart Sep. 1 at 4:55 PM
0 · Reply
BeefStewart
BeefStewart Sep. 1 at 3:02 PM
$ADMA 🫣
0 · Reply
mcclain23theoracle
mcclain23theoracle Aug. 31 at 12:47 PM
$ADMA this is a little better but keep going...
0 · Reply
mcclain23theoracle
mcclain23theoracle Aug. 31 at 11:05 AM
$ADMA wtf is this things problem??!! I'm going to kick Google assistant in the virtual nuts for this suggestion!
0 · Reply
Orange99
Orange99 Aug. 28 at 11:23 PM
$ADMA Some still shorting the stock. CEO did some real damage to the company’s credibility during Bivigam fiasco. ADMA’s reported short interest rose to 22.68 million shares as of August 14, up from 21.92 million at July 31—an increase of about 765,000 shares, or 3.5%. Short interest now represents approximately 10.5% of the public float, with about 8 days to cover. The August 14 data were published on August 25, 2026.
1 · Reply
BeefStewart
BeefStewart Aug. 28 at 10:17 PM
$ADMA 🥹
0 · Reply